Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Divi's Laboratories up; Citi calls it their 'top pick'

** Shares of Divi's Laboratories DIVI.NS rise 3% to 6,561 rupees, its biggest jump in three months

** Brokerage Citi says 2026 can be an inflection year for DIVI, calls it their 'top' pharma pick in India

** Adds co has strong pipeline catalysts over the next 12 months; generic segment expected to witness a recovery

** Expcts co's revenue to expand by 3 times and EBITDA to rise 4 times over FY25-FY30e

** Citi has a "buy" rating on co with PT at 9,140 rupees

** DIVI rated "hold" on avg by 27 analysts covering it; median PT at 6780 rupees - data compiled by LSEG

** In 2025, DIVI gained ~5%

 (Reporting by Komal Salecha)

 ((Komal@thomsonreuters.com;))

Recent news on Divi's Laboratories

See all news